An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the ...

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors.

Results have been positive, with SHR-1701 demonstrating improvements in overall survival, but taking market share will be a ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

On Monday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.01 which represents a slight increase of $0.60 or 1.21% from the prior close of $49.41. The stock opened at ...

Solving adherence issues with prodrugs, examining whether PBMs are to blame for high drugs prices in the US, developing ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Acquire the skills, knowledge and hands-on experience for a career as a Pharmaceutical Analyst in Industry or Academia. WHO ARE YOU? You are probably a recent physical or life sciences graduate – ...